Csaba Farsang

11.5k total citations
105 papers, 2.2k citations indexed

About

Csaba Farsang is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Csaba Farsang has authored 105 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Cardiology and Cardiovascular Medicine, 22 papers in Endocrinology, Diabetes and Metabolism and 17 papers in Surgery. Recurrent topics in Csaba Farsang's work include Blood Pressure and Hypertension Studies (50 papers), Hormonal Regulation and Hypertension (17 papers) and Heart Rate Variability and Autonomic Control (15 papers). Csaba Farsang is often cited by papers focused on Blood Pressure and Hypertension Studies (50 papers), Hormonal Regulation and Hypertension (17 papers) and Heart Rate Variability and Autonomic Control (15 papers). Csaba Farsang collaborates with scholars based in Hungary, Italy and Canada. Csaba Farsang's co-authors include George Kunos, Sverre E. Kjeldsen, J. Kapocsi, Lisa Naditch‐Brûlé, Zoltán Járai, Walter Zidek, Stefano Perlini, Katalin Farkas, Alberto Zanchetti and Endre Kolossváry and has published in prestigious journals such as Science, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Csaba Farsang

96 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Csaba Farsang Hungary 25 1.1k 505 441 415 387 105 2.2k
Shuntaro Kagiyama Japan 24 704 0.6× 291 0.6× 461 1.0× 161 0.4× 289 0.7× 54 1.9k
Osamu Iimura Japan 32 1.4k 1.2× 738 1.5× 551 1.2× 146 0.4× 484 1.3× 251 3.5k
Roland Veelken Germany 33 1.7k 1.5× 622 1.2× 512 1.2× 205 0.5× 323 0.8× 126 3.0k
Cristina Sierra Spain 30 980 0.9× 219 0.4× 561 1.3× 159 0.4× 218 0.6× 140 2.6k
Manuel Worcel France 26 1.7k 1.5× 556 1.1× 650 1.5× 173 0.4× 271 0.7× 86 3.1k
James J. Morton United Kingdom 30 1.4k 1.2× 673 1.3× 474 1.1× 176 0.4× 386 1.0× 62 3.0k
O. B. Holland United States 26 639 0.6× 1.1k 2.2× 414 0.9× 234 0.6× 521 1.3× 76 2.4k
Francis B. Gabbai United States 32 1.2k 1.1× 434 0.9× 449 1.0× 96 0.2× 490 1.3× 80 3.2k
E D Frohlich United States 27 1.5k 1.3× 411 0.8× 330 0.7× 122 0.3× 275 0.7× 63 2.4k
Hironobu Sanada Japan 27 745 0.7× 848 1.7× 861 2.0× 99 0.2× 310 0.8× 61 2.1k

Countries citing papers authored by Csaba Farsang

Since Specialization
Citations

This map shows the geographic impact of Csaba Farsang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Csaba Farsang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Csaba Farsang more than expected).

Fields of papers citing papers by Csaba Farsang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Csaba Farsang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Csaba Farsang. The network helps show where Csaba Farsang may publish in the future.

Co-authorship network of co-authors of Csaba Farsang

This figure shows the co-authorship network connecting the top 25 collaborators of Csaba Farsang. A scholar is included among the top collaborators of Csaba Farsang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Csaba Farsang. Csaba Farsang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Burnier, Michel, Krzysztof Narkiewicz, György Rokszin, et al.. (2024). Effect of single-pill versus free equivalent combinations on persistence and major adverse cardiovascular events in hypertension: a real-world analysis. Journal of Hypertension. 43(3). 405–412. 2 indexed citations
2.
Farsang, Csaba. (2014). Efficacy and Tolerability of Fixed-Dose Combination of Perindopril/Indapamide in Type 2 Diabetes Mellitus: PICASSO Trial. Advances in Therapy. 31(3). 333–344. 14 indexed citations
3.
Perlini, Stefano, Lisa Naditch‐Brûlé, Csaba Farsang, Walter Zidek, & Sverre E. Kjeldsen. (2012). Pulse pressure and heart rate in patients with metabolic syndrome across Europe: insights from the GOOD survey. Journal of Human Hypertension. 27(7). 412–416. 17 indexed citations
4.
Járai, Zoltán, et al.. (2011). Management of hypertensive crises. 15(6). 249–254. 1 indexed citations
5.
Grassı, Guıdo, Renata Cífková, Stéphane Laurent, et al.. (2010). Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study. European Heart Journal. 32(2). 218–225. 63 indexed citations
6.
Blanco‐Colio, Luis Miguel, José Luis Martín‐Ventura, Carmen Gómez‐Guerrero, et al.. (2008). Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. European Journal of Pharmacology. 586(1-3). 259–265. 35 indexed citations
7.
8.
Farsang, Csaba. (2007). Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Pressure. 16(sup2). 19–24. 12 indexed citations
9.
Farsang, Csaba, et al.. (2005). Treatment of hypertension in dialysed patients. Journal of Hypertension. 23(1). 222–226. 4 indexed citations
10.
Farkas, Katalin, János Nemcsik, Endre Kolossváry, et al.. (2005). Impairment of skin microvascular reactivity in hypertension and uraemia. Nephrology Dialysis Transplantation. 20(9). 1821–1827. 40 indexed citations
11.
Krum, Henry, Peter E. Carson, Csaba Farsang, et al.. (2004). Effect of Valsartan Added to Background ACE Inhibitor Therapy in Patients with Heart Failure: Results from Val-HeFT. European Journal of Heart Failure. 6(7). 937–945. 70 indexed citations
12.
Papademetriou, Vasilios, Csaba Farsang, Dag Elmfeldt, et al.. (2004). Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension. Journal of the American College of Cardiology. 44(6). 1175–1180. 140 indexed citations
13.
Farkas, Katalin, Endre Kolossváry, Zoltán Járai, János Nemcsik, & Csaba Farsang. (2004). Non-invasive assessment of microvascular endothelial function by laser doppler flowmetry in patients with essential hypertension. Atherosclerosis. 173(1). 97–102. 109 indexed citations
14.
15.
Kjeldsen, Sverre E., Serap Erdine, Csaba Farsang, Peter Sleight, & Guiseppe Mancia. (2002). 1999 WHO/ISH Hypertension guidelines - highlights & ESH update. Journal of Hypertension. 20(1). 153–155. 34 indexed citations
16.
Farsang, Csaba. (2001). Moxonidine: Clinical Profile. Journal of clinical and basic cardiology. 4(3). 197–200. 7 indexed citations
17.
Kjeldsen, Sverre E., Ingrid Os, Csaba Farsang, et al.. (2000). European Society of Hypertension Scientific Newsletter, Update on Hypertension Management. Journal of Hypertension. 18(9). 1345–1346. 10 indexed citations
18.
Farsang, Csaba, et al.. (1987). Effect of two years' Cavinton treatment on the ECG.. PubMed. 35(3). 125–8. 1 indexed citations
19.
Farsang, Csaba, et al.. (1977). Effect of vasopressin on myocardial reactive hyperaemia in the isolated fibrillating dog heart.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 34(3). 169–81. 2 indexed citations
20.
Farsang, Csaba, et al.. (1977). Effect of norepinephrine on myocardial reactive hyperaemia in the isolated fibrillating dog heart.. PubMed. 34(3). 155–67. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shuntaro Kagiyama Breakdown of academic impact, for papers by Osamu Iimura Breakdown of academic impact, for papers by Roland Veelken Breakdown of academic impact, for papers by Cristina Sierra Breakdown of academic impact, for papers by Manuel Worcel Breakdown of academic impact, for papers by James J. Morton Breakdown of academic impact, for papers by O. B. Holland Breakdown of academic impact, for papers by Francis B. Gabbai Breakdown of academic impact, for papers by E D Frohlich Breakdown of academic impact, for papers by Hironobu Sanada
Rankless by CCL
2026